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Abstract
Proangiogenic enzyme thymidine phosphorylase (TP) is a promising target for anticancer therapy, yet its action in non-small
cell lung carcinoma (NSCLC) is not fully understood. To elucidate its role in NSCLC tumor growth, NCI-H292 lung
mucoepidermoid carcinoma cells and endothelial cells were engineered to overexpress TP by viral vector transduction.
NSCLC cells with altered expression of transcription factor Nrf2 or its target gene heme oxygenase-1 (HO-1) were used to
study the regulation of TP and the findings from pre-clinical models were related to gene expression data from clinical
NSCLC specimens. Overexpression of Nrf2 or HO-1 resulted in upregulation of TP in NCI-H292 cells, an effect mimicked by
treatment with an antioxidant N-acetylcysteine and partially reversed by HO-1 knockdown. Overexpression of TP attenuated
cell proliferation and migration in vitro, but simultaneously enhanced angiogenic potential of cancer cells supplemented
with thymidine. The latter was also observed for SK-MES-1 squamous cell carcinoma and NCI-H460 large cell carcinoma cells.
TP-overexpressing NCI-H292 tumors in vivo exhibited better oxygenation and higher expression of IL-8, IL-1b and IL-6. TP
overexpression in endothelial cells augmented their angiogenic properties which was associated with enhanced generation
of HO-1 and VEGF. Correlation of TP with the expression of HO-1 and inflammatory cytokines was confirmed in clinical
samples of NSCLC. Altogether, the increased expression of IL-1b and IL-6 together with proangiogenic effects of TP-
expressing NSCLC on endothelium can contribute to tumor growth, implying TP as a target for antiangiogenesis in NSCLC.
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Introduction
Lung tumors rank as the top cause of cancer-related deaths
worldwide, with non-small cell lung cancer (NSCLC) being the
most prevalent. NSCLC patients are often diagnosed with
advanced disease, when systemic chemotherapy is the major
therapeutic option. Since tumor growth and metastasis are
dependent on angiogenesis, mechanisms governing new blood
vessel formation have been targeted for intervention in lung cancer
[1]. However, addition of anti-VEGF agents to conventional
chemotherapy resulted only in slight improvement of median
survival [1,2] with patients experiencing tumor recurrence due to
emergence of drug resistance to antiangiogenic agents, underlining
an urgent need for new targets for combinatorial treatments.
Thymidine phosphorylase (TP, E.C.2.4.2.4) is a pyrimidine
salvage synthesis pathway enzyme, which is also known for its
proangiogenic properties. TP catalyzes reversible phosphorolysis of
thymidine into thymine and 2-deoxy-D-ribose-1-phosphate (dRP),
which is further dephosphorylated to 2-deoxy-D-ribose (dR). The
enzyme and its sugar products stimulate endothelial cell migration
and tube formation in vitro and enhance angiogenesis in various
models in vivo [3]. TP is frequently overexpressed in human tumors,
including NSCLC [3,4] and has been shown to correlate with
higher microvessel density, more advanced tumor stage, metastasis
and poor prognosis [3]. Proangiogenic action of TP in tumors, apart
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from the direct action of its products on endothelial cells, may also
involve the stimulation of expression of other angiogenic factors
such as VEGF, interleukin-8 (IL-8) or heme oxygenase-1 (HO-1)
[5,6]. Consequently, targeting TP with small-molecule inhibitors is
currently investigated as a novel antiangiogenic strategy [7].
Nevertheless, for the development of effective combinatorial
chemotherapeutics, retaining enzymatic activity of TP may be
necessary as it catalyzes an important step in activation of
fluoropyrimidine-based agents such as capecitabine, which has
been proposed as alternative treatment for advanced NSCLC [8].
This dual function of TP in tumor growth and therapy implies that
inhibiting protumoral effects of the enzyme may require targeting its
downstream mediators. Elucidating the mechanisms of regulation
and tumor-promoting actions of TP is therefore of crucial
importance.
Nrf2 (nuclear factor (erythroid-derived 2)-like 2) is a transcrip-
tion factor regulating cellular antioxidant responses [9]. It is
frequently constitutively active in tumors, including lung cancer,
and may be further induced by anticancer treatments. It drives
expression of cytoprotective genes leading to the development of
resistance to cytotoxic agents [10]. One of Nrf2 targets is HO-1,
which converts heme into CO, ferrous iron and biliverdin, and
which has been demonstrated to mediate Nrf2-driven resistance of
NSCLC cells to chemotherapy [11,12]. Interestingly, both
proteins play roles in promotion of angiogenesis: the action of
HO-1 upstream and downstream angiogenic VEGF and SDF1a is
well established [13], and the involvement of Nrf2 in regulation of
angiogenic IL-8 has been demonstrated [14–16].
Here we investigate the biological role of TP focusing on
angiogenesis and the interplay with Nrf2 and HO-1 in non-small
cell lung cancer and endothelial cells. Our results show the effects
of TP overexpression in NSCLC cells in vitro and in vivo and
highlight the importance of proangiogenic action of the enzyme.
Materials and Methods
Plasmids and viral vectors
Plasmid pBK-RSV-TP harboring human TP cDNA was kindly
provided by Dr. S. Liekens (Rega Institute for Medical Research,
K.U. Leuven, Belgium). Plasmid pEF(Blue)-Nrf2 containing
human Nrf2 cDNA was kindly gifted by Dr. J.A. Johnson
(Division of Pharmaceutical Sciences, University of Wisconsin-
Madison, USA) [17]. Construction of retroviral vectors (RVs) RV-
TP and RV-Nrf2 was conducted as described in Supplementary
Methods (File S1). Retroviral plasmid pMSCV-Luc containing
luciferase expression cassette for production of RV-Luc was
obtained from Addgene. All RVs including a control RV-empty
vector (LNCX2) were produced as described in [18].
Adenoviral vectors (AdVs) harboring TP cDNA (AdTP) were
developed as described in Supplementary Methods (File S1) and
control vectors with GFP (AdGFP) as reported previously [16].
Cell lines and culture conditions
Human NSCLC cell lines: NCI-H292 (mucoepidermoid
carcinoma, purchased from ATCC), A549 (adenocarcinoma,
obtained from Prof. Jakub Golab, Warsaw Medical University,
Warsaw, Poland) and NCI-H460 (large cell carcinoma, purchased
from ATCC) were cultured in RPMI 1640 (PAA) and SK-MES-1
(squamous cell carcinoma, purchased from ATCC) was cultured in
MEM (Gibco), each supplemented with 10% fetal bovine serum
(PAA) and penicillin (100 U/mL)/streptomycin (10 mg/mL) (Sig-
ma) (pen/strep). Human microvascular endothelial cells (HMEC-
1, obtained from Dr Francis Candal, Center for Disease Control
and Prevention, Atlanta, USA) were cultured in MCDB 131
supplemented with 10% FBS, L-glutamine 2 mM, pen/strep,
EGF 10 ng/mL and hydrocortisone 1 mg/mL. Primary human
umbilical vein endothelial cells (HUVEC) were isolated as
described previously [19] and cultured in M199 (PAA) supple-
mented with 20% FBS, pen/strep and endothelial cell growth
supplement ECGS 30 mg/L (Millipore).
All cells were maintained in standard culture conditions: 37uC,
5% CO2, 95% humidity. For the investigation of the effects of
hypoxia cells were placed for 24 or 48 hours in a chamber
(Biospherix USA) under controlled gas atmosphere 1% O2, 5%
CO2 and 94% N2 placed at 37uC in a cell culture incubator.
For establishment of cell lines NCI-H292-Luc-TP (NCI-TP)
and NCI-H292-Luc-Nrf2 (NCI-Nrf2) stably overexpressing lucif-
erase and respective transgenes and control NCI-H292-Luc-EV
(NCI-EV) modified with empty vector, cells were transduced with
retroviral vectors. First, an infection with RV-transgene or RV-
empty vector (RV-EV) was performed and stably transformed cells
were selected by geneticin (1 mg/mL), which was followed by
transduction with RV-Luc and selection by hygromycin (0.3 mg/
mL). NCI-H292-Luc-HO-1 (NCI-HO1) cell line was developed
and validated earlier in our laboratory [20]. For maintenance of
transgene expression cells were routinely kept in standard medium
additionally supplemented with geneticin (0.5 mg/mL) and
hygromycin (0.1 mg/mL). For experiments cells were seeded in
medium without antibiotics.
Transient TP overexpression and stimulation of cells with
NAC or TP substrate
Thymidine (Thd) and N-acetylcysteine (NAC) were purchased
from Sigma Aldrich. For transient TP overexpression in ECs,
HMEC-1 and HUVEC cells were transduced with adenoviral
vectors AdTP or control AdGFP at MOI = 10 for 24 h and then
stimulated with Thd for additional 24 h in complete medium. For
transient TP overexpression in NSCLC cells, SK-MES-1 and
NCI-H460 were transduced at MOI = 20 and MOI = 40, respec-
tively, and stimulated with 1 mM Thd in medium supplemented
with 2% FBS 48h post-transduction.
Real-time RT PCR
mRNA levels of genes were determined by quantitative RT
PCR. RNA was isolated with either Qiazol (Qiagen) or using
RNeasy Plus Micro Kit (Qiagen) according to the manufacturer’s
instructions. 1 mg of RNA was reverse-transcribed into cDNA
using oligo-dT primers with RevertAid Premium First Strand
cDNA Synthesis Kit (Fermentas). Real-time PCR was performed
using 30 ng of sample with QuantiTect SYBR Green (Qiagen,
analysis of in vitro experiments) or SYBR Premix Ex Taq II
(Takara, analysis of in vivo experiments) according to the
manufacturer’s instructions on LightCycler 480 II system (Roche).
Gene expression was calculated according to DCt or DDCt
methods with EF2 as a reference gene, with error bars calculated
as standard deviations of the means, divided by !(N-1), where N
was the number of independent experiments. Error pro-
pagation was not taken into account, what is some limitation of
our study.
Western blot analysis and ELISA
Western blot for HO-1 was performed as in [19]. For the
detection of human TP mouse mAb P-GF.44C (Calbiochem) was
used. Production of human VEGF and IL-8 in culture media and
human IL-8, IL-1b and IL-6 in tumor lysates was quantified using
DuoSet ELISA Kits (R&D) according to the manufacturer’s
protocols. Total protein concentration in the samples was
Regulation and Action of TP in NSCLC
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measured by BCA method. Data were normalized by pre-assay
dilutions of tumor lysates to an equal concentration of 1 mg/
mL.
Reporter gene assay for measurement of Nrf2
transcriptional activity
Assay was performed as already described in [15].
Gene silencing experiment
Cells were transfected with 50 nM siRNA (Stealth RNAi HO-1
siRNA and control Stealth RNAi Negative Control siRNA,
Invitrogen) using Lipofectamine 2000 reagent (Invitrogen) accord-
ing to the manufacturer’s instructions.
Cell proliferation and migration
Cell proliferation was measured by colorimetric assay of BrdU
incorporation (Cell Proliferation ELISA, Roche) according to the
vendor’s instruction. In order to investigate cell migration, cells
were grown to full confluence and serum-starved for 24 h to block
proliferation. Scratch was made on the monolayer with a pipette
tip. Migration was followed by time lapse microscopy (Zeiss
Axiovert 200 M) for 6-8 different fields for each condition. Mean
covered area was calculated at different time points and expressed
as the percentage of scratch area at time zero using ImageJ
software.
Angiogenesis assays in vitro
Tube formation assay on Matrigel was performed as already
described [21]. NSCLC cells were incubated in medium
containing 2% FBS in normoxia and hypoxia for 48 h,
conditioned medium was collected and mixed at 1:1 vol/vol with
MCDB 131 supplemented with 2% FBS and antibiotics without
other additives for stimulation of HMEC-1 or HUVEC. Spheroid
assay on HUVEC cells was performed as previously [19].
Animal experiments
Ethics statement. All animals were handled in strict
accordance with good animal practice and all animal work was
approved by the CNREEA 03 (Comité national de réflexion
éthique sur l’expérimentation animale) Campus CNRS d’Orléans
Ethics Committee in France.
6-week old female athymic Swiss nude mice were purchased
from Charles River (France). For establishment of NCI-TP and
control NCI-EV tumor xenografts, exponentially growing cells
were harvested using Cell Dissociation Solution (Sigma) and
resuspended in PBS. 56106 cells in 100 mL were injected
subcutaneously into the right leg of each mouse (10 animals/cell
line). Tumor growth was monitored for 5 weeks by caliper
measurements, tumor volume was calculated according to the
formula V = D6d260.5 (V is the tumor volume, D is the biggest
dimension; d is the smallest dimension).
Measurement of tumor oxygenation
Oxygenation of tumor tissue was measured by OxyLite sensor
system based on ruthenium fluorescence quenching by O2 (Oxford
Optronix).
Analysis of clinical material
Ethics statement. Human studies were approved by Local
Ethical Committee of the Collegium Medicum of the Jagiellonian
University in Krakow, Poland. Patients have expressed their
written consent to participation in the study.
Biopsies of primary tumors and tumor metastases to lymph
nodes (if present) were collected during surgery from 24 patients
suffering from NSCLC adenocarcinoma. Patients were treated at
the Clinic of Thoracic Surgery, Jagiellonian University Medical
College, 31-202 Kraków, Poland.
Figure 1. Effect of differential Nrf2/HO-1 expression on TP
expression in NSCLC in vitro and in vivo. A. Basal TP, Nrf2 and HO-1
protein levels in A549 and NCI-H292 NSCLC cell lines indicating possible
association of TP expression with Nrf2/HO-1 axis. B. Basal Nrf2
transcriptional activity in NSCLC cell lines measured by reporter gene
assay using plasmid harboring luciferase gene under the control of
antioxidant response element (ARE) (n = 3, *p,0.05 NCI-H292 vs A549).
C–D. Increased TP mRNA and protein expression in NCI-H292 cell lines
stably overexpressing Nrf2 or HO-1 (n = 4, *p,0.05 control empty
vector (EV) vs transgene overexpression) E. TP mRNA (left) and protein
expression (right, densitometric analysis of WB in lower panel) in vivo in
control and HO-1-overexpressing NCI-H292 xenografts (established as
described in [20]) corroborates the in vitro data (n = 5, *p,0.05 NCI-HO1
vs NCI-EV).
doi:10.1371/journal.pone.0097070.g001
Regulation and Action of TP in NSCLC
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Statistical analysis
Unless stated otherwise, results show mean 6 SEM of at least 3
independent experiments performed in duplicates. Unpaired
Student’s t-tests were used to assess whether the means of two
groups differed significantly. For comparison of multiple groups
one-way ANOVA analysis with Tukey post-test was employed.
Differences with a value of p,0.05 were considered statistically
significant.
Results
TP is differentially expressed in NSCLC cells with varying
levels of Nrf2 and heme oxygenase-1
We investigated TP expression in NSCLC cell lines A549 and
NCI-H292 originating from different histological types of tumors –
adenocarcinoma and mucoepidermoid carcinoma, respectively.
Western blot analysis revealed that A549 adenocarcinoma displays
high basal expression of TP, while the enzyme level is very low in
NCI-H292 (Fig. 1A). As the two cell lines are known to differ in
activity of transcription factor Nrf2 and its target gene HO-1, both
being expressed at higher level in A549 than in NCI-H292 ([22],
Fig. 1A,B), we investigated whether the Nrf2/HO-1 axis could be
involved in the regulation of TP. Indeed, when Nrf2 and HO-1
were independently stably overexpressed in NCI-H292 cells (Fig.
S1A, [20]), which have low basal Nrf2 and HO-1, the induction of
TP was observed in both NCI-Nrf2 and NCI-HO1 cells
(Fig. 1C&D, respectively). This expression pattern was also
confirmed in vivo in subcutaneous HO-1-overexpressing xenograft
tumors derived from NCI-HO1 cells in nude mice (Fig. 1E).
Nrf2-binding sites within the TP promoter have not been
identified (analysis not shown) suggesting that the regulation is
indirect. Since HO-1 is a known target of Nrf2 and was
significantly upregulated in NCI-Nrf2 cells (Fig. S1B), we next
aimed to determine whether the effect of Nrf2 was HO-1-
dependent. NCI-Nrf2 cells were transfected with siRNA against
HO-1 (Fig. S2), which led to a partial downregulation of TP
expression in both Nrf2-overexpressing cells and control cells
transduced with empty vector (NCI-EV) (Fig. 2A), implying that
HO-1 plays a role in the regulation of TP in NSCLC, yet its
involvement in the effect of Nrf2 is minor. Moreover, treatment of
NCI-EV cells with an antioxidant N-acetylcysteine resulted in a
dose-dependent upregulation of TP (Fig. 2B), mimicking the
regulation of the enzyme by Nrf2/HO-1 overexpression. Since the
stimulation of control cells with HO-1 products failed to reproduce
the upregulation of TP found in HO-1 overexpressing cells (Fig.
S3), the effect of Nrf2/HO-1 could be attributed to attenuation of
oxidative stress, as we have already shown that NCI-HO1 cells
have lower level of reactive oxygen species [20].
TP overexpression attenuates proliferation and migration
of NCI-H292 cells but enhances angiogenic potential of
NSCLC cell lines in vitro
Next, we aimed to investigate the direct effects of TP itself on
proliferation and migration of NCI-H292 cells. A stable cell line
overexpressing both luciferase and TP (NCI-TP) was established
by retroviral transduction and validated for TP expression
(Fig. 3A). Unexpectedly, proliferation of NCI-TP cells was
inhibited (Fig.3B). Scratch assay showed that migratory potential
of the NCI-TP cells was also attenuated (Fig. 3C, File S2 & S3).
Downregulation of mRNA levels of matrix metalloproteinases
(MMPs) MMP-1 and MMP-2 was also observed (Fig. S4) that
could potentially negatively affect tumorigenic potential of NCI-
H292 cells in vivo.
Since the major role of TP in tumor growth is thought to be
associated rather with its proangiogenic properties [23], we next
focused on elucidating the role of TP in modulation of
angiogenesis in our NCSLC model. Under standard conditions
no effect of TP overexpression/TP products on angiogenic
potential of tumor cells could be observed (Fig. S5). Nevertheless,
the major trigger of angiogenic switch in vivo is oxygen deprivation.
Therefore, to better mimic the environment of a growing tumor,
we placed the cells under hypoxia and provided them with
thymidine, which can be released from the necrotic core of tumor.
While the inhibitory effects of TP overexpression on proliferation
Figure 2. Regulation of TP by Nrf2/HO-1 axis in NCI-H292 cells. A. HO-1 and TP mRNA and protein expression in NCI-H292 cells with HO-1
knockdown. NCI-Nrf2 and NCI-EV control cells were transfected with 50 nM siRNA against HO-1 (siHO1) or control scrambled sequence (siSCR) for
72 h leading to downregulation of TP expression following HO-1 silencing. (n = 4, *p,0.05 NCI-Nrf2 vs NCI-EV, #p,0.05 siHO1 vs siSCR). B. Effect of
antioxidant N-acetylcysteine (NAC) on TP expression. NCI-EV cells were stimulated with indicated concentrations of NAC for 24 h resulting in a dose-
dependent upregulation of TP. (n = 3, * p,0.05 control vs stimulation).
doi:10.1371/journal.pone.0097070.g002
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and migration in NSCLC cells were unaffected by either hypoxia
and/or thymidine (Fig. S6), altered conditions revealed enhanced
angiogenic potential of NCI-TP cells, as evidenced by Matrigel
tube formation assay with conditioned media (Fig. 4A). It was
associated with the upregulation of IL-8 protein production by
tumor cells (Fig. 4B) and the induction of HO-1 (Fig. 4C) that
could be indicative of elevated oxidative stress in TP-overexpress-
ing cells, which is consistent with the findings from other tumor
types [5]. Importantly, TP-overexpressing cells exhibited en-
hanced angiogenic potential in the presence of thymidine also
under normoxic conditions (Fig. S7).
We next investigated whether TP modulates angiogenic
potential of tumor cells originating from other NSCLC histological
types, namely squamous cell carcinoma SK-MES-1 cell line and
NCI-H460 large cell carcinoma. Conditioned media collected
from hypoxic cells transiently overexpressing TP following
adenoviral vector transduction and stimulation with Thd caused
enhanced branching of endothelial cells in comparison to control
AdGFP-transduced cells for both cell types (Fig. 4D,G), which was
accompanied by increased production of IL-8 by SK-MES-1 cells
(Fig. 4E). Induction of HO-1 by TP was observed under normoxic
conditions (Fig. 4F,I).
TP modulates expression of inflammatory cytokines in
vivo
To determine how the complex effects of TP overexpression on
proliferation, migration and angiogenic potential of NCI-H292
cells observed in vitro would affect tumor development in vivo,
tumor cells were implanted subcutaneously into nude mice and
tumor growth was monitored for 5 weeks. TP overexpression
tended to accelerate growth of the NSCLC xenografts (Fig. 5A)
(p,0.1 NCI-TP vs NCI-EV at 4 and 5 weeks). Moreover, NCI-TP
tumors showed an insignificant trend (p = 0.2) towards enhanced
invasion of tumor-draining lymph nodes (Fig. S8). As cell
proliferation and migration are impaired by TP overexpression
(Fig. 3B-C), we presumed the differences in angiogenic properties.
Indeed, measurement of tumor oxygenation performed at the end
of the experiment showed that NCI-TP tumors were significantly
better oxygenated than tumors derived from control cells, which
coincided with increased production of hIL-8 in the former tumors
(Fig. 5B,C). Importantly, in our previous research using the NCI-
H292 xenografts we have shown that enhanced tumor oxygena-
tion corroborates enhanced tumor vascularization in this model
[20]. Nevertheless, although the TP overexpression was confirmed
to be retained in xenografts (Fig. 5D,E), no differences in levels of
either HO-1 or other angiogenic factors could be detected in
comparison with control tumors (Fig. 5D, Fig. S9A-D). To better
understand the mechanism underlying the effect of TP overex-
pression on NSCLC in vivo, we determined the expression of
inflammatory cytokines in the tumors. Human interleukin-1b and
interleukin-6 levels were significantly increased in NCI-TP tumors
(Fig. 5F&G). Also the expression of TNFa tended to be higher in
TP-overexpressing tumors, but it did not reach statistical
significance (Fig. S9E).
Interplay of TP, HO-1 and inflammatory cytokines in
clinical NSCLC specimens
We performed preliminary validation of our findings using
clinical material of primary tumors and tumor-infiltrated lymph
nodes collected during surgery from patients suffering from lung
adenocarcinoma. While there were no differences in either TP, IL-
1b or IL-6 expression between the primary and secondary tumor
specimens (Fig.5 H-J), it is noteworthy that the basal expression of
TP was high relative to constitutive gene EF2 in tumor tissue
(mean TP/EF2 = 2.202), which is comparable with the TP/EF2
levels obtained in our TP-overexpressing xenografts (mean TP/
EF2 = 1.027, see Fig. 5E). The relative gene/EF2 ratios are also
similar for the interleukins, which shows that our xenograft model
closely paralleled clinical situation. We found a significant
correlation between HO-1 and TP expressions (Spearman Rank
Correlation, R = 0.556; p = 0.028). What is more, a significant
correlation of TP with IL-1b (R = 0.514, p = 0.001) and IL-6
(R = 0.519, p = 0.002) was observed thus confirming our data from
the animal model showing a potential novel effect of TP
upregulation in the carcinoma of the lung.
Figure 3. Effect of TP overexpression on proliferation and
migration of NCI-H292 cells in vitro. A. Validation of the model –
upregulation of TP mRNA and protein levels in NCI-H292 cell line stably
overexpressing TP, established as described in Materials and Methods
(n = 3). B. Relative basal proliferation rates of NCI-EV and TP-
overexpressing cells measured by incorporation of bromodeoxyuridine
(BrdU) (n = 4). C. Basal migration rates of NCI-EV and NCI-TP cells
determined by scratch assay (n = 4) (scale bar – 200 mm) * p,0.05 NCI-
TP vs NCI-EV
doi:10.1371/journal.pone.0097070.g003
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TP overexpression enhances angiogenic potential of
endothelial cells
Interleukin-1b was demonstrated to induce expression of TP in
primary macrovascular human endothelial cells HUVEC [24]. We
reproduced this effect in a human microvascular endothelial cell
line HMEC-1 (Fig. 6A), suggesting the regulation was common for
different endothelial cell types. This observation raised a question
whether TP-dependent upregulation of inflammatory cytokines in
cancer cells could possibly contribute to modulation of tumor
angiogenesis through modulation of TP in endothelium. There-
Figure 4. Effect of TP overexpression on angiogenic potential of NSCLC cells in vitro. A. Increased angiogenic potential of TP
overexpressing cells in hypoxia in presence of thymidine. NCI-H292 cells were stimulated with 1 mM Thd for 48 h under 1% oxygen and conditioned
media were applied on HMEC-1 cells seeded on Matrigel. The number of branchpoints formed by HMEC-1 treated with conditioned media from
either empty-vector transduced NCI-H292 cells (NCI-EV) or TP-transduced (NCI-TP) has been calculated (scale bar – 200 mm) (n = 3). B. Production of
angiogenic factors in TP-overexpressing NCI-H292 cells under hypoxia in presence of 1 mM Thd for 24h quantified by ELISA detecting upregulation of
IL-8 in NCI-TP cell line (n = 4). C. Increased HO-1 mRNA (left) and protein (right) expression in TP-overexpressing cells in presence of 1 mM Thd in
hypoxia after 24 h (n = 3). * p,0.05 NCI-TP vs NCI-EV. D–I. Enhanced angiogenic potential of lung squamous cell carcinoma SK-MES-1 and large cell
carcinoma cells NCI-H460 following transient TP overexpression. SK-MES-1 (D–F, n = 3) and NCI-H460 (G–I, n = 4) cells were transduced with AdTP or
control AdGFP for 48 h, stimulated with 1 mM Thd for additional 48 h under 1% oxygen (D–E&G–H) or normoxia (F&I). Conditioned media were
used in Matrigel assay on HUVEC cells (D&G) and measurement of IL-8 production (E&H) and HO-1 expression was assayed in cell lysates (F&I). * p,
0.05 AdTP vs AdGFP
doi:10.1371/journal.pone.0097070.g004
Regulation and Action of TP in NSCLC
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Figure 5. Effect of TP overexpression on NCI-H292 xenograft tumor growth and data from clinical NSCLC samples. A. Measurement of
tumor volume by caliper. NCI-EV and NCI-TP cells were xenografted into nude mice as described in Materials and Methods. B. Measurement of tumor
oxygenation at 5 weeks of tumor growth (n = 7 for NCI-EV, n = 9 for NCI-TP). C–G. mRNA (left) and protein (right) expression of human IL-8 (C), HO-1
(D), TP (D,E) and inflammatory cytokines (F–G) in xenograft tumors indicates upregulation of secretion of IL-8, IL-1b and IL-6 in NCI-TP xenografts
Regulation and Action of TP in NSCLC
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fore, next we investigated the effects of TP overexpression in ECs.
Introduction of TP into HUVEC enhanced the abilities of
endothelial cells to form tubule-like structures in Matrigel and
angiogenic sprouting in collagen gel (Fig. 6B,C). This was
accompanied by induction of proangiogenic HO-1 (Fig. 6D,E),
which was further potentiated in HUVEC cells in the presence of
excess of TP substrate (Fig. 6E). In HMEC-1 model, a
concomitant increase in VEGF production was observed following
TP overexpression (Fig. 6F), while no effect could be observed for
HUVEC (Fig. 6G), which may not release VEGF [25–27]. These
results imply a novel proangiogenic action of TP within ECs,
possibly through induction of other angiogenic proteins. The
mechanism, however, may be strictly endothelial cell-type specific.
Discussion
The salient finding of the present study is the demonstration
that TP can be upregulated in NCI-H292 cells by activation of
Nrf2/HO-1 pathway possibly through amelioration of oxidative
stress. Induction of TP attenuated cell proliferation and migration
in vitro. On the other hand, increased expression of IL-1b and IL-6
in TP-expressing tumors, as well as enhanced proangiogenic
effects of TP-expressing NSCLC cells on endothelial cells, have
been observed (Fig. 7).
In 2009, Lu et al. published the proof-of-concept in vivo study
showing the feasibility of direct thymidine phosphorylase inhibi-
tion as a novel approach to antiangiogenesis in NSCLC [28].
Translation of these findings into clinic, however, requires
extended knowledge concerning the biological roles of the enzyme.
Here, we provide novel insights into the regulation and
protumoral actions of TP in non-small cell lung cancer.
We have demonstrated the regulation of thymidine phosphor-
ylase by Nrf2 and HO-1 in mucoepidermoid carcinoma of the
lung, as the manipulation of Nrf2 or HO-1 levels led to
concomitant modulation of TP levels in vitro and in vivo and HO-
1 expression correlated with TP in clinical NSCLC specimens. To
our knowledge, this is the first observation linking TP with Nrf2
and indicating that HO-1 may act upstream of TP in cancer. Thus
far, coexpression of TP and HO-1 has already been reported in
clinical specimens of human malignant vertical growth melanomas
in macrophages [29]. Studies in vitro implicated that HO-1 could
only play a role downstream of TP, as was described in vascular
smooth muscle cells or bladder carcinoma, where TP overexpres-
sion resulted in induction of HO-1 expression [5,30]. We provide
here mechanistic data showing that the regulation is indirect,
potentially involving modulation of oxidative status of the cell, as
the effects of Nrf2 or HO-1 on TP expression were mimicked by
treatment of control cells with an antioxidant N-acetylcysteine.
Our data indicate that, apart from its established role in cancer
biology, Nrf2 may also be an important player in regulation of
tumor angiogenesis by enhancing the expression of proangiogenic
TP, thus warranting further research into the Nrf2/HO-1-TP
association in other tumor types. Moreover, positioning TP
downstream of Nrf2 and HO-1 would have interesting implica-
tions for the design of new anticancer treatments. HO-1 itself is a
validated therapeutic target as it is proangiogenic, antiapoptotic
and generally cytoprotective enzyme which plays an important
role in tumor development and therapy [31]. In NSCLC both
HO-1 and TP, as well as Nrf2, are known to contribute to cell
resistance to cisplatin, chemotherapeutic drug commonly used as a
first-line treatment in clinic [12,22,32]. In light of our findings,
targeting Nrf2 and/or HO-1 pathway would possibly concomi-
tantly affect TP, thus broadening inhibitory action on another
pathway.
Unexpectedly, we observed inhibition of the proliferation of
NCI-H292 cells overexpressing TP in vitro and attenuation of their
migratory potential. It was opposite to what has been observed in
other tumor types including breast, cervical, bladder and gastric
cancer (reviewed in [3]), showing that the effects of TP are cell
type dependent. However, despite the inhibitory influence of TP
on proliferation and migration of NSCLC cells in vitro, we show
that in vivo the overexpression of the enzyme tended to accelerate
tumor growth and increase local metastasis which was associated
with significant upregulation of proinflammatory cytokines,
interleukin-8 and better oxygenation of tumors. Accordingly, in
vitro angiogenesis assays showed that in the presence of TP
substrate, thymidine, NCI-TP cells enhanced the response of
endothelial cells, an effect replicated also in two other NSCLC cell
types: squamous carcinoma and large cell carcinoma. This broad
proangiogenic effect could be exerted by at least two actions. First,
it could be mediated directly by dRP and dR formed through TP
pathway from Thd released from the necrotic core of tumor. It has
been already shown that dR induces endothelial cell migration via
activation of focal adhesion kinase and integrin signaling [33].
Second, TP may modulate expression of other angiogenic factors,
as demonstrated in our study for interleukin-8 in NCI-H292 and
SK-MES-1 cells, which has been previously associated with TP in
other tumor types [5,34,35]. The upregulation of IL-8 in vivo could
also be a mechanism of possible potentiation of TP expression
within tumor microenvironment, as the chemokine was reported
to induce TP in human cells [36]. However, we could not observe
any difference in the expression of HO-1 or other angiogenic
factors between TP-overexpressing and control tumors in vivo. It
can be argued that additional modulation of angiogenic switch by
TP could have occurred earlier in tumor development and was not
possible to detect after 5 weeks of xenograft growth.
Nevertheless, the TP-overexpressing tumor cells exhibited
enhanced expression of IL-1b and IL-6. To our knowledge, this
is the first demonstration of such effect exerted by thymidine
phosphorylase, which finds additional confirmation in the gene
expression analysis in human clinical tumor specimens. Both IL-1b
and IL-6-mediated inflammation may contribute to NSCLC-
related morbidity and mortality [37,38]. Moreover, the inflam-
matory cytokines can promote tumor growth and metastasis in an
autocrine manner by enhancing cancer cell proliferation and
activating pro-survival signaling pathways [39,40]. Upregulation
of IL-1b and IL-6 could potentially serve as autocrine positive
feedback loop for TP in cancer cells and drive paracrine induction
of the enzyme in tumor microenvironment. Stimulation of TP
expression by these cytokines is a relatively well known pathway of
its regulation and has been observed in many cell types (reviewed
in [3]).
Indeed, here we confirmed that treatment with IL-1b results in
upregulation of endogenous TP in endothelium. Since studies
showing proangiogenic actions of TP on endothelial cells
published so far only focused on the effects of exogenous
recombinant TP and its sugar products, we overexpressed TP in
HUVEC. Such intrinsic induction of TP in endothelium
augmented their angiogenic properties, showing that paracrine
induction of TP in endothelial cells by factors produced by TP-
(n = 5, *p,0.05 NCI-TP vs NCI-EV). H–J. mRNA expression of TP (H) and inflammatory cytokines (I–J) in biopsies from human primary and secondary
lung adenocarcinomas.
doi:10.1371/journal.pone.0097070.g005
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Figure 6. Effect of TP overexpression in endothelial cells on angiogenic potential. A. Effect of IL-1b on TP expression in HMEC-1 cells.
Stimulation with 0.3 ng/mL human recombinant IL-1b for 24 h led to upregulation of TP in endothelial cells (ECs). (n = 3, * p,0.05 control vs IL-1b).
B–C. ECs were transduced with adenoviral vectors AdTP or control AdGFP at MOI = 10 for 48 h when Matrigel assay on HUVEC in the presence of
VEGF (50 ng/mL) (B) and spheroid assay on HUVEC (VEGF 50 ng/mL) (C) was performed, indicating enhanced angiogenic potential of TP-
overexpressing cells (n = 3, *p,0.05 AdTP vs AdGFP, # p,0.05 control vs VEGF) (scale bar – 100 mm) D–G. 24 h post-transduction with AdV
endothelial cells were stimulated with 1 mM Thd for next 24 h. Analysis of HO-1 expression by quantitative PCR and western blot in HMEC-1 (D) and
in HUVEC (E) shows induction of HO-1 in TP-overexpressing ECs, associated with increased VEGF expression in HMEC-1 (F) while there is no effect in
HUVEC (G). (n = 4, * p,0.05 AdTP vs AdGFP, $ p,0.05 control vs Thd).
doi:10.1371/journal.pone.0097070.g006
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overexpressing cancer cells might also contribute to proangiogenic
action of the enzyme in tumor microenvironment. Importantly,
cells overexpressing TP displayed higher expression of another
proangiogenic enzyme – HO-1. Our previous works [21,41], as
well as other studies [42,43], have shown that HO-1 induces
endothelial cell sprouting, plays an important role in mediating
proangiogenic actions of VEGF and SDF-1 and induces VEGF
expression [44]. Accordingly, in HMEC-1 cells VEGF expression
paralleled HO-1 induction in response to upregulation of TP.
Taken together, our data show the regulation of TP expression
by HO-1 and Nrf2 in NCI-H292 cells. Moreover, we demonstrate
evidence for additional mechanism of protumoral action of TP
involving upregulation of inflammatory cytokines and increased
angiogenic response of endothelial cells, which provides further
rationale for targeting this enzyme for antiangiogenesis in non-
small cell lung carcinoma.
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were collected from unstimulated NCI-H292 cells under normoxia
for 24 h. HUVEC spheroids were stimulated with CM or VEGF
10 ng/mL for 72 h (representative experiment, *p,0.05 control
vs stimulation). B. Basal mRNA expression of angiogenic factors in
TP-overexpressing cells in normoxia. C. mRNA expression of
angiogenic factors in NCI-EV cells stimulated with TP products.
Cells were stimulated with 200 mM 2-deoxyribose (dR)/2-
deoxyribose-1-phosphate (dRP) for 24 h in normoxia.
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Figure S6 Effects of hypoxia and TP substrate on
proliferation (A) and migration (B) of TP-overexpressing
cells. Cells were incubated for 24 h under hypoxia in the
presence of 1 mM Thd. Scratch assay was performed under
hypoxic conditions. * p,0.05 NCI-TP vs NCI-EV, # p,0.05
normoxia vs hypoxia.
(PDF)
Figure S7 Effect of TP overexpression on angiogenic
potential of NCI-H292 cells in vitro. A. NCI-H292 cells were
stimulated with 1 mM Thd for 48 h in normoxia and conditioned
media were applied on HMEC-1 cells seeded on Matrigel. The
number of branchpoints formed by HMEC-1 treated with
conditioned media from either empty-vector transduced NCI-
H292 cells (NCI-EV) or TP-transduced (NCI-TP) has been
calculated. B. Increased production of IL-8 in TP-overexpressing
NCI-H292 cells stimulated with 1 mM Thd for 24 h (n = 4). * p,
0.05 NCI-TP vs NCI-EV.
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Figure S8 Effect of TP overexpression on metastasis in
vivo. A. Relative Luc activity in inguinal lymph nodes proximal to
tumor xenograft measured ex vivo upon sacrifice of the animals by
bioluminescence imaging on IVIS Lumina II Imaging System
(Caliper Life Science) [Centre d’Imagerie du Petit Animal TAAM
UPS44, CNRS, Orléans] following intraperitoneal injection of
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